Zöller M, Matzku S
Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg.
Immunobiology. 1999 Sep;201(1):1-21. doi: 10.1016/S0171-2985(99)80043-6.
There is increasing evidence that tumors express putative target molecules for a therapeutic immune reaction. Yet, tumor cells lack the prerequisites for appropriate antigen presentation and--hence--the immune system does not respond. This difficulty can probably be circumvented when tumor antigens are processed by conventional antigen presenting cells. Thus, the identification of immunogenic tumor-associated antigens may allow new modes of vaccination with the hope of adding a fourth and hopefully powerful weapon to surgery, radiation and chemotherapy in the fight against cancer.
越来越多的证据表明，肿瘤表达出可能成为治疗性免疫反应靶点的分子。然而，肿瘤细胞缺乏进行适当抗原呈递的先决条件，因此免疫系统不会产生反应。当肿瘤抗原由传统抗原呈递细胞进行处理时，这一难题或许可以得到解决。因此，鉴定具有免疫原性的肿瘤相关抗原可能会带来新的疫苗接种方式，有望为抗癌斗争中的手术、放疗和化疗增添第四种且有望强有力的武器。
